GlassScriptPhysician profile
Kendal C Laux
NPI 1902257629
$465.47
in general payments reported to CMS, 2019-2025
11 companies · $113 in 2025
The $113 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11.90 · 2020: $37.56 · 2021: $66.96 · 2022: $78.34 · 2023: $84.17 · 2024: $73.84 · 2025: $113.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $271.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $270.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $124.86 | 2021-2025 | Evenity, Prolia, Repatha |
| Abbvie INC. | $119.97 | 2022-2023 | |
| Inspire Medical Systems, INC. | $52.28 | 2025 | Inspire |
| Teva Pharmaceuticals USA, INC. | $42.00 | 2021-2022 | |
| Verona Pharma, INC. | $26.78 | 2025 | Ohtuvayre |
| Astrazeneca Pharmaceuticals LP | $25.99 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.97 | 2021 | |
| Merck Sharp & Dohme LLC | $16.37 | 2024 | Capvaxive, Vaxelis, Gardasil 9 |
| Mylan Specialty L.P. | $13.78 | 2021 | |
| Coopersurgical, INC. | $11.90 | 2019 | |
| Lilly USA, LLC | $11.57 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kendal Laux listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.